Peptide-MHC Stability and Immunogenicity
Author Information
Author(s): Miles Kim M., Miles John J., Madura Florian, Sewell Andrew K., Cole David K.
Primary Institution: Cardiff University, School of Medicine
Hypothesis
Do heteroclitic peptides designed to improve MHC binding actually enhance stability compared to their wildtype counterparts?
Conclusion
Heteroclitic peptides do not always show significantly improved stability over their wildtype counterparts, despite being more immunogenic.
Supporting Evidence
- Heteroclitic peptides designed with optimal MHC binding motifs do not always form more stable pMHCs than their wildtype counterparts.
- The study utilized a novel SPR method to assess pMHC stability in real time.
- Findings suggest that the increased immunogenicity of heteroclitic peptides may not be solely due to enhanced stability.
Takeaway
The study found that changing parts of a peptide to make it fit better with MHC doesn't always make it more stable, but it can still make the immune system react more strongly.
Methodology
The study used a surface plasmon resonance (SPR) assay and a cell surface binding assay to compare the stability of wildtype and heteroclitic peptide-MHC complexes.
Limitations
The study primarily focused on a limited number of peptides and may not generalize to all heteroclitic peptides.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website